Last updated: February 27, 2026
What is the drug associated with NDC 83324-0072?
NDC 83324-0072 corresponds to Rimegepant Oral, a calcitonin gene-related peptide (CGRP) receptor antagonist used to treat migraines. It is marketed under the brand name Nurtec ODT by Biohaven Pharmaceuticals.
Market Overview
Market Size and Growth
- The global migraine drug market was valued at approximately $4.1 billion in 2022 and is projected to reach $7.4 billion by 2030, at a compound annual growth rate (CAGR) of 7.6% (Fortune Business Insights, 2023).
- Rimegepant captured a significant share within the CGRP inhibitor segment, which grew from $1.2 billion in 2021 to an estimated $2.4 billion in 2023.
Competitive Landscape
-
Rimegepant (Nurtec ODT) competes with other CGRP inhibitors, including:
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Ubrogepant (Ubrelvy)
-
Ubrogepant, developed by AbbVie, shares similar indications but has a different administration route (oral versus injectable).
Market Adoption
- Nurtec ODT gained FDA approval in January 2020 for both acute treatment and prevention of migraines.
- Market penetration is higher among neurology specialists, with primary care physicians adopting at a slower pace.
- Patients favor oral formulations over injections for ease of use.
Price Analysis
Current Pricing Structure
| Product |
Wholesale Acquisition Cost (WAC) |
Estimated Out-of-Pocket Cost |
Notes |
| Nurtec ODT (per tablet) |
~$44 |
$20-$50 |
Price varies by pharmacy and insurance plan coverage |
| Ubrelvy (per tablet) |
~$50 |
$30-$60 |
Slightly higher, competing with Nurtec in some markets |
Pricing Trends
- Nurtec ODT's patient cost has remained relatively stable since launch, with slight reductions due to insurance negotiations.
- Price increases in specialty drugs are limited by payer pressure and pharmacy benefit manager (PBM) negotiations.
Future Price Projections
| Year |
Predicted Price per Tablet |
Rationale |
| 2023 |
~$44 |
Stabilized market, competitive pricing, no major price hikes noted in recent years |
| 2025 |
~$42 |
Anticipated volume growth and increased biosimilar or generic competition possibly reducing price pressure |
| 2030 |
~$40 |
Continued competition and market saturation may lead to marginal price decreases |
Note: Price reductions may accelerate if biosimilar or generic versions of rimegepant enter the market, following patent expiration. Patent expiry is projected around 2031, based on current patent filings and legal timelines.
Regulatory and Patent Environment
- Patent protection exists until approximately 2031, preventing generic entry till then.
- FDA exclusivity extensions could influence timing but are unlikely to delay generic competition significantly.
Market Drivers and Barriers
Drivers
- Rising prevalence of chronic migraines, estimated at 12% of the US population.
- Growing preference for oral medication over injectable forms.
- Expanded insurance coverage following FDA approval for both acute and preventive uses.
Barriers
- High drug cost may limit access for some patient segments.
- Payer restrictions, such as prior authorization, reduce market penetration.
- Competition from injectable CGRP inhibitors offering different dosing schedules.
Investment and R&D Outlook
- Biohaven's focus on expanding indications and formulations may sustain revenue beyond 2030.
- Potential biosimilars or generics could risk market share post patent expiry.
- R&D investments in combination therapies might diversify the portfolio but could also dilute market focus.
Key Takeaways
- NDC 83324-0072 (Nurtec ODT) functions in a rapidly expanding migraine segment, competing heavily with other CGRP inhibitors.
- Market size for the CGRP segment is projected to nearly double by 2030, driven by increasing migraine prevalence.
- Current retail prices are around $44 per tablet, with minor future price reductions anticipated.
- Patent protection extends until roughly 2031, after which generic competition is likely to pressure prices.
- Payer dynamics and patent expiration will influence both market share and pricing in the upcoming years.
FAQs
Q1. When will generic versions of rimegepant likely enter the market?
Patent expiration is expected around 2031, with biosimilars/generics possibly launching shortly thereafter.
Q2. How does Nurtec ODT compare price-wise to competitors?
Nurtec ODT's retail price (~$44 per tablet) is comparable but slightly lower than similar oral CGRP inhibitors like Ubrelvy (~$50 per tablet), with price variations depending on pharmacy and insurance.
Q3. What factors could influence price reductions?
Introduction of generics or biosimilars, increased competition, and payer negotiations could lower prices.
Q4. What are the growth prospects for Nurtec ODT?
Market expansion is fueled by rising migraine prevalence, expanded FDA indications, and growing consumer preference for oral treatments.
Q5. What regulatory changes could impact the market?
Patent extensions or new FDA indications could temporarily delay generic entry; conversely, patent challenges or expirations will promote generic competition.
References
[1] Fortune Business Insights. (2023). Migraine Drugs Market Size, Share & Trends Analysis Report.
[2] FDA. (2020). Nurtec ODT (rimegepant) Approval Announcement.
[3] IQVIA. (2023). prescription drug market data, Q1 2023.
